Cost-effectiveness of treprostinil versus epoprostenol in patients with pulmonary arterial hypertension: A Canadian analysis

Canadian Respiratory Journal

Volumn 12, Issue 8, 2005, Pages 419-425

  Einarson, Thomas R ^a,b   Granton, John T ^c   Vicente, Colin ^b   Walker, John H ^b,d   Engel, Greg ^e   Iskedjian, Michael ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PharmIdeas Research and Consulting Inc   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d BROCK UNIVERSITY   (Canada)

^e Northern Therapeutics Inc   (Canada)

Author keywords

Cost effectiveness; Epoprostenol; Health economics; Pulmonary arterial hypertension; Treprostinil

Indexed keywords

PROSTACYCLIN; UNIPROST;

ARTICLE; CANADA; CLINICAL TRIAL; COHORT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DISEASE ASSOCIATION; DRUG COST; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; INJECTION SITE INFECTION; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SENSITIVITY ANALYSIS; SEPSIS;

EID: 30944436464     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2005/719451     Document Type: Article

References (30)

1. Pass SE, Dusing ML. Current and emerging therapy for primary pulmonary hypertension. Ann Pharmacother 2002;36:1414-23.
2. British Cardiac Society Guidelines and Medical Practice Committee, and approved by the British Thoracic Society and the British Society of Rheumatology. Recommendations on the management of pulmonary hypertension in clinical practice. Heart 2001;86(Suppl 1):I1-13.
3. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 1998;352:719-25. (Erratum in 1999;353:74).
4. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-9.
5. Canadian Pharmacists Association. Compendium of Pharmaceuticals and Specialties: The Canadian Drug Reference for Health Professionals. Toronto: Webcom Limited, 2003.
6. Health Canada - Health Products and Food Branch. Notices of Compliance: Prescription pharmaceuticals for human use, 1997. (Version current at November 10, 2005).
7. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: The impact of epoprostenol therapy. Circulation 2002;106:1477-82.
8. Health Canada - Health Products and Food Branch. Notices of Compliance: Prescription pharmaceuticals for human use, 2002. (Version current at November 10, 2005).
9. Simonneau G, Barst RJ, Galie N, et al; Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4.
10. McLaughlin V. Improvement in exercise tolerance with treprostinil is dose related for pulmonary arterial hypertension. The American Thoracic Society 2002 International Conference. Atlanta, Georgia, May 20 to 23, 2002.
11. McLaughlin VV, Gaine SP, Barst RJ, et al; Treprostinil Study Group. Efficacy and safety of treprostinil: An epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 2003;41:293-9.
12. Gibbs JS, Arneson CP, Mottola C. Chronic infusion of treprostinil is safe, and appears to prolong survival over a three-year period in patients with pulmonary arterial hypertension. Circulation 2002;106(Suppl II):575. (Abst)
13. Vachiery J, Naeije R. Treprostinil for pulmonary hypertension. Expert Rev Cardiovasc Ther 2004;2:183-91.
14. Highland KB, Strange C, Mazur J, Simpson KN. Treatment of pulmonary arterial hypertension: A preliminary decision analysis. Chest 2003;124:2087-92.
15. Ontario Ministry of Health and Long-Term Care. Ontario Guidelines for Economic Analysis of Pharmaceutical Products. Toronto: Institutional Services Branch, Ministry of Health, 1994.
16. Canadian Coordinating Office for Health Technology Assessment. Guidelines for Economic Evaluation of Pharmaceuticals: Canada, 2nd edn. Ottawa: CCOHTA, 1997.
17. Ontario Ministry of Health. Schedule of Benefits: Laboratory Services under the Health Insurance Act. Toronto: Institutional Services Branch of the Ministry of Health, 1999.
18. Ontario Ministry of Health. Schedule of Benefits: Physician Services under the Health Insurance Act. Toronto: Institutional Services Branch of the Ministry of Health, 2003.
19. Régie de l'assurance maladie du Québec. Liste des Médicaments. Québec: RAMQ, 2003.
20. Vachiery JL, Hill N, Zwicke D, Barst R, Blackburn S, Naeije R. Transitioning from iv epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Chest 2002;121:1561-5.
21. Galie N, Manes A, Branzi A. Medical therapy of pulmonary hypertension. The prostacyclins. Clin Chest Med 2001;22:529-37.
22. Widlitz A, Barst RJ. Pulmonary arterial hypertension in children. Eur Respir J 2003;21:155-76.
23. Schulman K, Glick H, Buxton M, et al. The economic evaluation of the FIRST study: Design of a prospective analysis alongside a multinational phase III clinical trial. Flolan International Randomized Survival Trial. Control Clin Trials 1996;17:304-15.
24. Banayan D, Witt J, McCarthy M, Granton JT. The direct and indirect costs of chronic intravenous epoprostenol in patients with pulmonary arterial hypertension. American Thoracic Society 99th International Conference. Seattle, Washington, May 16, 2003.
25. Schulman KA, Buxton M, Glick H. Results of the economic evaluation of the first study. A multinational prospective economic evaluation. FIRST Investigators. Flolan International Randomized Survival Trial. Int J Tech Assess Health Care 1996;12:698-713.
26. Alberta Institute for Health Economics. Hospital per diem costs. Edmonton: Institute for Health Economics, 2000.
27. Norris C, Jacobs P, Rapoport J, Hamilton S. ICU and non-ICU cost per day. Can J Anaesth 1995;42:192-6.
28. Statistics Canada. Consumer Price Index - Health Care. CANSIM II - v735519 Table 326-0001. Ottawa: Statistics Canada, 2003.
29. Letarte J, Longo CJ, Pelletier J, Nabonne B, Fisher HN. Patient characteristics and costs of severe sepsis and septic shock in Quebec. J Crit Care 2002;17:39-49.
30. Treprostinil (Remodulin) for pulmonary arterial hypertension. Med Lett Drugs Ther 2002;44:80-2.